Strong Memorial Hospital Participating in Cannabis-Based Drug Trials

Researchers at Strong Memorial Hospital are involved in clinical trials with a drug derived from cannabis.

The Investigational New Drug is called Epidiolex, and it's different from medical marijuana available through the state's dispensaries. It's almost pure Cannabidiol, which is a chemical compound in cannabis thought to help reduce seizures.

Currently, URMC is involved in an FDA-approved double blind study to test the effectiveness of the drug, the results of which should be available in about a year.

Researchers are now planning for another study, called a Compassionate Use Study, to test the side effects of Epidiolex, and how it reacts with other medications. This study will involved children and young adults.

Doctor David Wang is leading the research at URMC, where he's an Associate Professor of Neurology and Pediatrics. He says patients age one-to-21 with severe, treatment-resistant epilepsy will be eligible to participate.

"Which is defined as, you have...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.